Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Blue Jet HealthcareBOM:544009 +2.46%65 PE Ratio (TTM) is 44.81 as of Aug. 19, 2026, which is 14% above its 10-year median of 39.47. GuruFocus rates BOM:544009 with a GF Score™ of 65/100 and a GF Value™ of ₹522.79 (Modestly Overvalued). The stock has 10 warning signs investors should review. Among 279 Biotechnology companies, Blue Jet Healthcare ranks worse than 67.74% on this metric.
The PE Ratio (TTM), or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). As of today (2026-08-19), Blue Jet Healthcare's share price is
₹607.20.
Blue Jet Healthcare's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 was ₹13.55. Therefore, Blue Jet Healthcare's PE Ratio (TTM) for today is 44.81.
Warning Sign:
Blue Jet Healthcare Ltd stock PE Ratio (=44.81) is close to 1-year high of 46.
The historical rank and industry rank for Blue Jet Healthcare's PE Ratio (TTM) or its related term are showing as below:
BOM:544009'
s PE Ratio (TTM) Range Over the Past 10 Years
Min: 20.26 Med: 39.47 Max: 66.91
Current: 44.81
During the past 6 years, the highest PE Ratio (TTM) of Blue Jet Healthcare was 66.91. The lowest was 20.26. And the median was 39.47.
BOM:544009's PE Ratio (TTM) is ranked worse than 67.74% of 279
companies
in the Biotechnology industry
Industry Median: 27.21
vs BOM:544009: 44.81
During the past 12 months, Blue Jet Healthcare's average EPS without NRIGrowth Rate was -34.50% per year.
During the past 3 years, the average EPS without NRIGrowth Rate was 14.60% per year.
During the past 5 years, the average EPS without NRIGrowth Rate was 12.20% per year.
During the past 6 years, Blue Jet Healthcare's highest 3-Year average EPS without NRI Growth Rate was 17.30% per year. The lowest was 4.90% per year. And the median was 14.60% per year.
Blue Jet Healthcare's EPS (Basic) for the
three
months ended in Jun. 2026 was ₹4.51.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Jun. 2026 was ₹13.55.
Blue Jet Healthcare (BOM:544009) PE Ratio (TTM) Explanation
The PE Ratio (TTM) can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio (TTM) is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.
In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio (TTM) is positive. Also for stocks with the same PE Ratio (TTM), the one with faster growth business is more attractive.
If a company loses money, the PE Ratio (TTM) becomes meaningless.
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio (TTM) divided by the growth ratio. He thinks a company with a PE Ratio (TTM) equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio (TTM) of 20, instead of a company growing 10% a year with a PE Ratio (TTM) of 10.
Because the PE Ratio (TTM) measures how long it takes to earn back the price you pay, the PE Ratio (TTM) can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.
Investors need to be aware that the PE Ratio (TTM) can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratio (TTM)s are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio (TTM) is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio .
PE Ratio (TTM) can also be affected by non-recurring-items such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio (TTM).
Blue Jet Healthcare PE Ratio (TTM) Related Terms
Blue Jet Healthcare PE Ratio (TTM) Historical Data
* Premium members only.
The historical data trend for Blue Jet Healthcare's PE Ratio (TTM) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:544009 vs VRTX, REGN, RVMD: PE Ratio (TTM) Comparison
For the Biotechnology subindustry, Blue Jet Healthcare's PE Ratio (TTM), along with its competitors' market caps and PE Ratio (TTM) data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Blue Jet Healthcare PE Ratio (TTM) vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Blue Jet Healthcare's PE Ratio (TTM) distribution charts can be found below:
* The bar in red indicates where Blue Jet Healthcare's PE Ratio (TTM) falls into.
The PE Ratio (TTM), or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). It is the most widely used ratio in the valuation of stocks.
Blue Jet Healthcare's Share Price of today is ₹607.20.
Blue Jet Healthcare's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹13.55.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
There are at least three kinds of PE Ratio (TTM)s used by different investors. They are Trailing Twelve Month PE Ratio (TTM) or PE Ratio (TTM) (TTM), Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio (TTM) based on inflation-adjusted normalized PE Ratio (TTM) is called Shiller PE Ratio, after Yale professor Robert Shiller.
In the calculation of PE Ratio (TTM), the earnings per share used are the earnings per share over the past 12 months. For Forward PE Ratio, the earnings are the expected earnings for the next twelve months. In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.
For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.
Blue Jet Healthcare (BOM:544009) has a PE Ratio (TTM) of 44.81 as of Aug. 19, 2026. Trailing 12-month P/E ratio is the ratio of share price to a company's trailing 12-month earnings per share. View historical data on Blue Jet Healthcare and its competitors. This is 14% above median its historical median of 39.47. Over the past decade, Blue Jet Healthcare's PE Ratio (TTM) has ranged from 20.26 to 66.91. According to the industry distribution chart, Blue Jet Healthcare ranks #189 out of 279 companies in the Biotechnology industry, placing it in the top 67.7%.
Is Blue Jet Healthcare's PE Ratio (TTM) too high?
Blue Jet Healthcare's current PE Ratio (TTM) of 44.81 is 14% above median its 10-year median of 39.47. Over the past 10 years, this metric has ranged from a low of 20.26 to a high of 66.91. The Biotechnology industry median PE Ratio (TTM) is 27.21. Blue Jet Healthcare's value of 44.81 is 64.7% above this industry median. Based on the distribution chart, Blue Jet Healthcare ranks #189 out of 279 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Blue Jet Healthcare has a GF Score™ of 65/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Blue Jet Healthcare's PE Ratio (TTM) compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Blue Jet Healthcare ranks #189 out of 279 companies for PE Ratio (TTM). This places Blue Jet Healthcare in the lower half of its industry. The industry median PE Ratio (TTM) is 27.21. Blue Jet Healthcare's value of 44.81 is 64.7% above this benchmark. Historically, Blue Jet Healthcare's own PE Ratio (TTM) has ranged from 20.26 to 66.91 over the past decade. While the company's 10-year median is 39.47 vs. the industry median of 27.21, Blue Jet Healthcare has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PE Ratio (TTM) for a Biotechnology company?
The median PE Ratio (TTM) among Biotechnology companies is 27.21, based on 279 companies in the industry. Companies in the top quartile (top 25%) have a PE Ratio (TTM) significantly above this median, while those in the bottom quartile fall well below. However, PE Ratio (TTM) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Blue Jet Healthcare's current PE Ratio (TTM) of 44.81 is 64.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PE Ratio (TTM) mean?
A high PE Ratio (TTM) can signal that a stock is expensive relative to its fundamentals. Trailing 12-month P/E ratio is the ratio of share price to a company's trailing 12-month earnings per share. View historical data on Blue Jet Healthcare and its competitors. For the Biotechnology industry, the median PE Ratio (TTM) is 27.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Blue Jet Healthcare's current PE Ratio (TTM) is 44.81, which is 14% above median its own 10-year median of 39.47. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Blue Jet Healthcare stock overvalued right now?
Based on GuruFocus' analysis, Blue Jet Healthcare (BOM:544009) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹522.79, compared to a current price of ₹607.20 — trading 16.1% above its estimated fair value. The current PE Ratio (TTM) is 44.81, which is 14% above median its 10-year median of 39.47 and 64.7% above the Biotechnology industry median of 27.21. Blue Jet Healthcare's overall GF Score™ is 65/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PE Ratio (TTM) calculated?
PE Ratio (TTM) is calculated from a company's financial statements. For Blue Jet Healthcare (BOM:544009), the current PE Ratio (TTM) is 44.81 as of Aug. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Blue Jet Healthcare (BOM:544009) Overvalued in 2026?
Based on GuruFocus' analysis, Blue Jet Healthcare stock appears to be overvalued.
The current stock price of ₹607.20 is trading 16.1% above its estimated GF Value™ of ₹522.79.
GuruFocus considers Blue Jet Healthcare to be Modestly Overvalued.
Key valuation signals for BOM:544009:
PE Ratio (TTM): 44.81 (14% above median its 10-year median of 39.47)
GF Value™: ₹522.79 vs. price of ₹607.20 (16.1% above fair value)
Industry Position: 64.7% above the Biotechnology median (#189 of 279)
No single metric tells the full story. See the BOM:544009 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Blue Jet Healthcare Ltd is engaged in manufacturing of Pharma Intermediate, APIs used in Pharmaceutical and Healthcare Products. The operations of the company are organized in three product categories which are contrast media intermediates, artificial sweeteners, pharma intermediates, and active pharmaceutical ingredients. Geographically, it operates in Norway, France, India and Rest of the World.
65GF Score
Get the complete analysis for BOM:544009
PE Ratio (TTM) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:544009 has been successfully added to your 
